A single-dose Qß VLP vaccine against S100A9 protein reduces atherosclerosis in a preclinical model.
Adv Ther (Weinh)
; 5(10)2022 Oct.
Article
in En
| MEDLINE
| ID: mdl-36570039
ABSTRACT
The standard therapy for cardiovascular disease (CVD) is the administration of statins to reduce plasma cholesterol levels, but this requires lifelong treatment. We developed a CVD vaccine candidate that targets the pro-inflammatory mediator calprotectin by eliciting antibodies against the S100A9 protein. The vaccine, based on bacteriophage Qß virus-like particles (VLPs) displaying S100A9 peptide epitopes, was formulated as a slow-release PLGAVLP implant by hot-melt extrusion. The single-dose implant elicited S100A9-specific antibody titers comparable to a three-dose injection schedule with soluble VLPs. In an animal model of CVD (ApoE-/- mice fed on a high-fat diet), the implant reduced serum levels of calprotectin, IL-1ß, IL-6 and MCP-1, resulting in less severe aortic lesions. This novel implant was therefore able to attenuate atherosclerosis over a sustained period and offers a novel and promising strategy to replace the repetitive administration of statins for the treatment of CVD.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Adv Ther (Weinh)
Year:
2022
Document type:
Article
Affiliation country:
United States